Abstract
A 19-year-old nulliparous hirsute woman was evaluated for the very high serum levels of testosterone (T) and estradiol (E2) measured in an outside laboratory. Menarche had occurred at 11 years and was followed by regular menses. We confirmed the high levels of T (9–16 ng/ml, nv 0.2–0.8) and E2 (>1000 pg/ml, nv 30–120). LH and FSH were consistently high (73–118 mU/l and 18-29 mU/l, respectively; LH/FSH ratio=4.1-4.7) and responsive to iv GnRH (LH baseline=118 mU/l, 30 min=290; FSH baseline=25 mU/l, 30 min=46). The unstimulated values contrasted with those (LH=12, FSH=8 mU/l) measured in the outside laboratory, suggesting antigenically anomalous gonadotropins. 17-OH-progesterone was normal (0.5 ng/ml). After 1 mg dexamethasone, serum cortisol was normally suppressed (24→0.4 μg/dl), T declined minimally (9→8.6 ng/ml) and E2 remained high (>1000 pg/ml). An exploratory laparotomy was performed, and two enlarged ovaries with multiple cysts as in a typical polycystic ovarian syndrome (PCOS) were seen. Before the wedge resection of the ovaries, hormones were assayed in the ovary veins (right ovary: T=30 ng/ml, Pg=17 ng/ml, E2=>5000 pg/ml; left: T=14 ng/ml, Pg=14 ng/ml, E2=>5000 pg/ml). Histologically, the follicle cysts showed luteinization of the theca interna; there was no evidence for ovary tumor in either ovary. After 21 days of 35 μg ethynyl-E2+2 mg cyproterone acetate (CA), E2=3,000 pg/ml, T=1.4 ng/ml, LH=10.5 mU/l and FSH=4.1 mU/l. After three cycles of the said therapy (but with 50 mg CA in the first 10 days of each cycle), E2 was 1600 pg/ml, T 1.7 ng/ml, LH 7.1 and FSH 4.6 mU/l. Based on similarities with the phenotype of the α estrogen receptor knockout female mice (αERKO), one possible explanation for the puzzling clinical and biochemical picture of our patient is resistance of αER to estrogens. This is the first case of PCOS with extremely high E2 and T. Thus, the differential diagnosis of high levels of E2±T should include PCOS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benjamin F, Toles A.W., Selzer V.L., Deutsch S. Excessive estradiol secretion in polycystic ovarian disease. Am. J. Obstet. Gynecol. 1993, 19: 1223–1226.
Bethea C.L. Stimulatory effect of estrogen on prolactin secretion from primate pituitary cells cultured on extracellular matrix and in serum-free medium. Endocrinology 1984, 115: 443–451.
Kawagoe S., Hiroi M. Effects of several estrogenic compounds on serum corticosteroid binding globulin (CBG) and the estrogen threshold for increasing CBG. Nippon Naibunpi. Gakkai. Zasshi. 1978, 54: 666–675.
Barnes R.B. The pathogenesis of polycystic ovary syndrome. Lessons from ovarian stimulation studies. J. Endocrinol. Invest. 1998, 21: 567–579.
Carr B.R. Disorders of the ovaries and female reproductive tract. In: Wilson J.D., Foster D.W., Kronenberg H.M., Larsen P.R. (Eds.), Williams Textbook of Endocrinology, 9th ed. W.B.Saunders, Philadelphia, USA, 1998, pp. 788–789.
Eastman R.C., de la Peña M.S., Moore W.T., Hao E., Merriam G.R. Acromegaly, hyperprolactinemia, gonadotropin-se-creting tumors and hypopituitarism. In: Moore W.T., Eastman R.C. (Eds.), Diagnostic Endocrinology. CBC Decker, Toronto, Canada, 1990, pp. 44–45.
Hall J.E., Taylor A.E., Hayes F.J., Crowley Jr. W.F. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J. Endocrinol. Invest. 1998, 21: 602–611.
Nillson C., Petterson K., Millar R.P., Coerver K.A., Matzuk M.M., Huhtaniemi I.T. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. International Collaborative Research Group. Fertil. Steril. 1997, 67: 998–1004.
Haavisto A.M., Petterson K., Bergendahl M., Virkamaki A., Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J. Clin. Endocrinol. Metab. 1995, 80: 1257–1263.
Adashi E.Y. Hypothalamic-pituitary dysfunction in polycystic ovarian disease. Endocrinol. Metab. Clin. North Am. 1988, 17: 649–666.
Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 1999, 20: 358–417.
Couse J.F., Bunch D.O., Lindzey J., Schomberg D.W., Korach K.S. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. Endocrinology 1999, 140: 5855–5865.
Sar M., Welsch F. Differential expression of estrogen receptor β and estrogen receptor α in the rat ovary. Endocrinology 1999, 140: 963–971.
Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T.C., Lubahn D.B., Korach K.S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 1994, 331: 1056–1061.
Gell J.S. Oh J., Rainey W.E., Carr B.R. Effect of estradiol on DHEAS production in the human adrenocortical cell line, H295R. J. Soc. Gynecol. Investig. 1998, 5: 144–148.
Zhuang L.Z., Adashi E.Y., Hsuch A.J. Direct enhancement of gonadotropin-stimulated ovarian estrogen biosynthesis by estrogen and clomiphene citrate. Endocrinology 1982, 110: 2219–2221.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartolone, L., Smedile, G., Arcoraci, V. et al. Extremely high levels of estradiol and testosterone in a case of polycystic ovarian syndrome. Hormone and clinical similarities with the phenotype of the α estrogen receptor null mice. J Endocrinol Invest 23, 467–472 (2000). https://doi.org/10.1007/BF03343757
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343757